Literature DB >> 26449664

Idiotype-specific CD4(+) T cells eradicate disseminated myeloma.

O A Haabeth1, A Tveita1, M Fauskanger1, K Hennig1, P O Hofgaard2, B Bogen1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26449664     DOI： 10.1038/leu.2015.278

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells.

Authors:  N Ghosh; I Gyory; G Wright; J Wood; K L Wright
Journal:  J Biol Chem       Date:  2001-01-30       Impact factor: 5.157

2.  The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma.

Authors:  L F Porrata; M A Gertz; S M Geyer; M R Litzow; D A Gastineau; S B Moore; A A Pineda; K L Bundy; D J Padley; D Persky; M Q Lacy; A Dispenzieri; D S Snow; S N Markovic
Journal:  Leukemia       Date:  2004-06       Impact factor: 11.528

3.  Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma--evaluation of T-cell responses by different read-out systems.

Authors:  Amir Osman Abdalla; Lotta Hansson; Ingrid Eriksson; Barbro Näsman-Glaser; Eva D Rossmann; Hodjattallah Rabbani; Håkan Mellstedt; Anders Osterborg
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

4.  Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules.

Authors:  B Bogen; B Malissen; W Haas
Journal:  Eur J Immunol       Date:  1986-11       Impact factor: 5.532

5.  MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.

Authors:  Mojun Zhao; Frederick L Flynt; Mei Hong; Han Chen; Carolyn A Gilbert; Nicole T Briley; Sophia C Bolick; Kenneth L Wright; Janet F Piskurich
Journal:  Mol Immunol       Date:  2007-02-14       Impact factor: 4.407

6.  Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.

Authors:  S Hong; H Li; J Qian; J Yang; Y Lu; Q Yi
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

7.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

8.  Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.

Authors:  Katy J McCann; Rosemary Godeseth; Lindsey Chudley; Ann Mander; Gianfranco Di Genova; Paul Lloyd-Evans; Jonathan P Kerr; Vladimir B Malykh; Matthew W Jenner; Kim H Orchard; Freda K Stevenson; Christian H Ottensmeier
Journal:  Cancer Immunol Immunother       Date:  2015-05-16       Impact factor: 6.968

Review 9.  How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Authors:  Ole Audun Werner Haabeth; Anders Aune Tveita; Marte Fauskanger; Fredrik Schjesvold; Kristina Berg Lorvik; Peter O Hofgaard; Hilde Omholt; Ludvig A Munthe; Zlatko Dembic; Alexandre Corthay; Bjarne Bogen
Journal:  Front Immunol       Date:  2014-04-15       Impact factor: 7.561

10.  A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease.

Authors:  Peter O Hofgaard; Henriette C Jodal; Kurt Bommert; Bertrand Huard; Jo Caers; Harald Carlsen; Rolf Schwarzer; Nicole Schünemann; Franziska Jundt; Mona M Lindeberg; Bjarne Bogen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240
View more
  9 in total

1.  Cancer: Precision T-cell therapy targets tumours.

Authors:  Cornelis J M Melief
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

2.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

3.  Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.

Authors:  Zhuting Hu; Donna E Leet; Rosa L Allesøe; Giacomo Oliveira; Shuqiang Li; Adrienne M Luoma; Jinyan Liu; Juliet Forman; Teddy Huang; J Bryan Iorgulescu; Rebecca Holden; Siranush Sarkizova; Satyen H Gohil; Robert A Redd; Jing Sun; Liudmila Elagina; Anita Giobbie-Hurder; Wandi Zhang; Lauren Peter; Zoe Ciantra; Scott Rodig; Oriol Olive; Keerthi Shetty; Jason Pyrdol; Mohamed Uduman; Patrick C Lee; Pavan Bachireddy; Elizabeth I Buchbinder; Charles H Yoon; Donna Neuberg; Bradley L Pentelute; Nir Hacohen; Kenneth J Livak; Sachet A Shukla; Lars Rønn Olsen; Dan H Barouch; Kai W Wucherpfennig; Edward F Fritsch; Derin B Keskin; Catherine J Wu; Patrick A Ott
Journal:  Nat Med       Date:  2021-01-21       Impact factor: 53.440

4.  Dietary suppression of MHC class II expression in intestinal epithelial cells enhances intestinal tumorigenesis.

Authors:  Semir Beyaz; Charlie Chung; Haiwei Mou; Khristian E Bauer-Rowe; Michael E Xifaras; Ilgin Ergin; Lenka Dohnalova; Moshe Biton; Karthik Shekhar; Onur Eskiocak; Katherine Papciak; Kadir Ozler; Mohammad Almeqdadi; Brian Yueh; Miriam Fein; Damodaran Annamalai; Eider Valle-Encinas; Aysegul Erdemir; Karoline Dogum; Vyom Shah; Aybuke Alici-Garipcan; Hannah V Meyer; Deniz M Özata; Eran Elinav; Alper Kucukural; Pawan Kumar; Jeremy P McAleer; James G Fox; Christoph A Thaiss; Aviv Regev; Jatin Roper; Stuart H Orkin; Ömer H Yilmaz
Journal:  Cell Stem Cell       Date:  2021-09-15       Impact factor: 25.269

5.  Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination.

Authors:  Markus Haug; Gaute Brede; Monika Håkerud; Anne Grete Nedberg; Odrun A Gederaas; Trude H Flo; Victoria T Edwards; Pål K Selbo; Anders Høgset; Øyvind Halaas
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

Review 6.  Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment.

Authors:  Hannah V Newnes; Jesse D Armitage; Katherine M Audsley; Anthony Bosco; Jason Waithman
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

7.  CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages.

Authors:  Ole Audun W Haabeth; Kjartan Hennig; Marte Fauskanger; Geir Åge Løset; Bjarne Bogen; Anders Tveita
Journal:  Blood Adv       Date:  2020-06-23

Review 8.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

9.  Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display.

Authors:  Anders Tveita; Marte Fauskanger; Bjarne Bogen; Ole Audun Werner Haabeth
Journal:  Oncotarget       Date:  2016-10-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.